Table 2.
Information on cinobufotalin combined with chemotherapy
| Included studies | Therapeutic regimen | Enrollment Period | Dosage of cinobufotalin | |
|---|---|---|---|---|
| Experimental group | Control group | |||
| Cha XT (2016)16 | Oxaliplatin+Tegafur+CF/SF+Cinobufotalina | Oxaliplatin+Tegafur+CF/SF | January 2013–March 2016 | 750 mg/time, 3 times/day |
| Chen GF (2012)17 | Capecitabine+Cinobufotalinb | Capecitabine | October 2006–October 2010 | 10 ml/time, 3 times/day |
| Chen HM (2009)18 | Paclitaxel+Cisplatin+5-Fu+Cinobufotalinb | Paclitaxel+Cisplatin+5-Fu | October 2005–December 2007 | 30 ml/time, 1 time/day |
| Cui P (2009)19 | FOLFOX+Cinobufotalinb | FOLFOX | 2004–2006 | 30 ml/time, 1 time/day |
| Guo CJ (2011)20 | Docetaxel+Cinobufotalinb | Docetaxel | March 2005–March 2010 | 20 ml/time, 1 time/day |
| Guo XY (2013)21 | FOLFOX+Cinobufotalinc | FOLFOX | January 2009–May 2010 | 1200 mg/time, 4 times/day |
| Huang Q (2014)22 | XELOX+Cinobufotalinb | XELOX | August 2009–August 2013 | 50 ml/time, 1 time/day |
| Li W (2016)23 | Capecitabine+Cinobufotalinb | Capecitabine | January 2012–January 2015 | 10-20 ml/time, 1 time/day |
| Li YX (2012)24 | Capecitabine+Cinobufotalinb | Capecitabine | January 2006–July 2011 | 10 ml/time, 1 time/day |
| Lu B (2016)25 | Capecitabine+Cinobufotalina | Capecitabine | January 2010–December 2012 | 500 mg/time, 3 times/day, |
| Lu CH (2014)26 | FOLFOX+Cinobufotalinb | FOLFOX | 2009–2013 | 20 ml/time, 1 time/day |
| Tian B (2012)27 | FOLFOX+Cinobufotalinb | FOLFOX | 2004–2006 | 30 ml/time, 1 time/day |
| Wang F (2014)28 | Cisplatin+5-Fu+Cinobufotalina | Cisplatin+5-Fu | ND | 500 mg/time, 3 times/day, |
| Wang WM (2010)29 | S-1+Cinobufotalina | S-1 | October 2011–October 2013 | 500 mg, 3 times/day |
| Wang YH (2009)30 | FOLFOX+Cinobufotalinb | FOLFOX | December 2004–May 2008 | 10-20 ml/time, 1 time/day |
| Wang ZF (2012)31 | FOLFOX+Cinobufotalinb | FOLFOX | December 2003–May 2008 | 20 ml/time, 1 time/day |
| Xiao XN (2018)32 | FOLFOX+Cinobufotalinb | FOLFOX | January 2008–December 2010 | 10-20 ml/time, 1 time/day |
| Xu DM (2015)33 | Docetaxel+Cisplatin+Cinobufotalinb | Docetaxel+Cisplatin | 2013–2016 | 20 ml/time, 1 time/day |
| Xu YM (2016)34 | Capecitabine+Cinobufotalinb | Capecitabine | June 2010–June 2011 | 20 ml/time, 1 time/day |
| Yang B (2017)35 | FOLFOX+Cinobufotalina | FOLFOX | January 2014–April 2015 | 750 mg/time, 3 times/day, |
| Yang F (2018)36 | XELOX+Cinobufotalinb | XELOX | January 2015–June 2017 | 20 ml/time, 1 time/day |
| Zhang CW (2001)37 | EOF+Cinobufotalina | EOF | May 2014–May 2015 | 200-500 mg/time, 3 times/day |
| Zhang RG (2004)38 | Etoposide+Leucovorin+5-Fu+Cinobufotalinb | Etoposide+Leucovorin+5-Fu | March 1999–December 2000 | 20 ml/time, 1 time/day |
| Zhang Y (2005)39 | HCPT+CF+5-Fu+Cinobufotalinb | HCPT+CF+5-Fu | July 1998–June 2003 | 20 ml/time, 1 time/day |
| Zheng YL (2007)40 | FOLFOX+Cinobufotalinb | FOLFOX | March 2002–February 2003 | 50 ml/time, 1 time/day |
| Zhu WK (2012)41 | Oxaliplatin+Capecitabine+Cinobufotalinb | Oxaliplatin+Capecitabine | March 2010–MArch 2011 | 30 ml/time, 1 time/day |
| Zou HP (2012)42 | EOF+Cinobufotalinb | EOF | May 2008–May 2011 | 20 ml/time, 1 time/day |
Notes: Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. a, cinobufotalin capsule; b, cinobufotalin injection; c, cinobufotalin tablet; S-1, Gimeracil and Oteracil Porassium Capsules.
Abbreviations: ND, non determined; CF, Calcium folinate; SF, Sodium folinate; Fu, Fluorouracil; HCPT, Hydroxycamptothecin; FOLFOX, Oxaliplatin+CF+5-Fu; XELOX, Oxaliplatin+Capecitabine; EOF, Epirubicin+Oxaliplatin+5-Fu.